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Colon  
Microscopic Colitis 
Background 
1. Definition  
o Chronic inflammatory bowel dz encompassing both lymphocytic colitis and 
collagenous colitis  
2. General info  
o Collagenous colitis:  
 Thickening of subepithelial basement membrane of colonic mucosa w/ a 
band of collagen 
o Lymphocytic colitis:  
 Intraepithelial lymphocytosis w/o collagen thickening 
Pathophysiology 
1. Pathology of dz  
o Not completely known  
o Normal radiologic and colonoscopic appearance of colon  
o Abnormal histologic appearance of colon  
o Leads to chronic watery diarrhea w/o bleeding  
2. Incidence and prevalence  
o Incidence of 10 per 100,000 person-years  
 Lymphocytic: 5.4 per 100,000 
 Collagenous: 4.6 per 100,000  
o Prevalence of 103 per 100,000 person-years  
 Lymphocytic: 63.7 per 100,000 
 Collagenous: 39.3 per 100,000 
3. Risk factors  
o Pt characteristics  
 Older age 
 Female 
o Assoc autoimmune dz  
 Hypothyroidism 
 Celiac dz 
 Diabetes mellitus 
 Rheumatoid arthritis 
 Asthma 
 Allergies 
4. Morbidity/mortality  
o Not assoc w/ incr mortality or severe deterioration 
o No incr risk of neoplasia 
Diagnostics 
1. History  
o Intermittent, chronic, non-bloody, watery diarrhea 
o Diarrhea up to 2 L or 4-9 episodes/d 
o Vague abdominal pain 
o Fecal urgency 
o Weight loss 
o Fatigue 
o Nausea 
2. Physical exam  
o Unremarkable 
o Vague abdominal tenderness 
o Weight loss 
3. Diagnostic testing  
o Laboratory evaluation  
 ESR may show slight elevation 
 Autoantibodies found in half of patients  
 RF, ANA, antimitochondrial antibodies, and anti-neutrophil 
cytoplasmic antibodies 
 Tissue transglutaminase antibody or antiendomysium antibody to rule out 
celiac dz 
 Stool culture to rule out infectious cause 
 Incr levels of stool inflammatory markers  
 Eosinophil protein X, myeloperoxidase, and tryptase 
o Diagnostic imaging  
 Normal radiologic appearance of colon 
o Other studies  
 Normal colonoscopic appearance of colon 
 Colon biopsy for Dx  
 Number and location of biopsies not established 
 Proximal biopsies improve sensitivity 
Differential Dx 
1. Key DDx  
o Irritable bowel syndrome  
o Ulcerative colitis 
o Crohn's dz 
o Diverticulitis 
o Ischemic colitis 
o Drug-induced colitis 
o Infectious colitis 
o Lactose intolerance 
o Celiac dz 
2. Extensive DDx  
o Hyperthyroidism 
o Carcinoid syndrome 
o VIPoma 
o Colon cancer 
o Other causes of abdominal pain and chronic diarrhea 
Therapeutics 
1. Reassure pt:  
o Dz has not been assoc w/ colonic neoplasia, incr mortality, or severe deterioration 
2. Discontinue any offending drugs 
3. Budesonide  
o Start at 9 mg/d for 4 wk 
o Treat over a 6-8 wk period  
o If in remission  
 Taper to 6 mg for 2 wk  
 Then 3 mg for 2 wk 
 Then discontinue 
o May continue dose of 9 mg/d for 12 wks before tapering if Sx are not controlled 
or if Sx recur on tapering  
4. Bismuth subsalicylate  
o Nine 262 mg tablets daily in 3 divided doses for 8 wk trial is reasonable in pt 
w/collagenous colitis  
5. Mesalamine  
o 800 mg TID with or w/o cholestyramine  
o 4 g daily may be effective for pts w/active collagenous or lymphocytic colitis  
6. Loperamide  
o May be used for symptomatic Tx of diarrhea  
7. Boswellia serrata extract, prednisolone and probiotics  
o No evidence on effectiveness  
8. Surgery  
o Rarely recommended or reported 
o Ileostomy may be procedure of choice in older pts w/severe, resistant dz 
Follow-Up 
1. Return to office  
o As needed if not responding to Tx 
2. Refer to specialist  
o Not indicated unless refractory to Tx 
3. Admit to hospital  
o Only if unable to manage as outpatient (rare) 
Prognosis 
1. Dz course variable w/alternating remissions and relapses  
o Good long-term prognosis 
2. Not assoc with incr mortality or severe deterioration 
3. 80% resolve spontaneously in less than 3 yrs  
4. Recurrence is common despite Tx  
5. No incr risk of neoplasia 
Prevention  
1. Limit drugs assoc w/dz 
2. Limit dietary factors that may exacerbate condition  
o Caffeine, alcohol, dairy products 
Patient Education 
1. http://digestive.niddk.nih.gov/ddiseases/pubs/collagenouscolitis/ 
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